View Author
prostate cancer psa-cre prostate cancer epithelial tumor month e 17k substitution mutation akt 1 expression 14 months inactivation control epithelial cells model mouse tissue development hyperplasia prostate lobes prostate epithelial cells apoptosi proliferation luminal epithelial cells 5 months patient pik 3ca proliferation rate adenocarcinoma staining prostate cancer development pten +/à mice recombination tumor development pten inactivation gland sample promoter hyperplasia /pin lesions substitution phospho-akt pik 3r control mice carcinoma lesion stage number luminal suppressor study prostate-specific growth tumours pten recombination cre expression pten exon 5 pleckstrin homology domain psa promoter change pin lesions fragment prostate weight pathway monoallelic cytokeratin www.aacrjournals.org function 9 months pten expression antibody weight littermate control littermates survival dysplasia adult caspase -3-positive cells van der korput biallelic
2 Most Recent Publications
|
E17K substitution in AKT1 in prostate cancer
(Article)
Boormans, J.L. Korsten, H. Ziel-van der Made, A.C. Leenders, G.J. van Verhagen, P.C.M.S. Trapman, J. |
2010-05-01
|
|
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
(Article)
Ziel-van der Made, A.C. Autar, B. Ma, X. Trapman, J. Korput, H.A.G.M. van der Vermeij, M. Duijn, P.W. van Cleutjens, C.B.J.M. Krijger, R.R. de Krimpenfort, P. Berns, A. Kwast, Th.H. van der |
2005-07-01
|